BiotechTube
Cinclus Pharma

Cinclus Pharma

Stockholm, Sweden· Est.
cincluspharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Cinclus Pharma is a private, clinical-stage biotech targeting the large and underserved market for gastroesophageal reflux disease (GERD) with its novel potassium-competitive acid blocker (PCAB), linaprazan glurate. The drug candidate has completed Phase II trials and represents a potential paradigm shift in acid suppression therapy, offering a differentiated mechanism of action and pharmacokinetic profile. The company is in an intensive development phase, scaling its organization to advance its lead asset toward late-stage trials and eventual global registration.

GastroenterologyInfectious Disease

Technology Platform

Development of Potassium-Competitive Acid Blockers (PCABs), a novel class of acid-suppressing drugs with a mechanism distinct from proton pump inhibitors (PPIs).

Funding History

2
Total raised:$75M
Series B$50M
Series A$25M

Opportunities

The large, global GERD market has a significant unmet need due to PPI non-responders, creating a substantial target population for a superior therapy.
The novel PCAB mechanism offers potential for faster onset, more consistent acid control, and better efficacy in severe disease, enabling premium pricing.
The asset also has potential in H.
Pylori eradication, providing an additional revenue stream.

Risk Factors

High clinical development risk as the single lead asset must succeed in costly and uncertain Phase III trials.
Intense competition from established PPIs (including generics) and other PCABs already on the market or in development.
Significant financing risk, requiring large capital inflows to fund late-stage development with no guaranteed revenue.

Competitive Landscape

The competitive landscape is dominated by generic proton pump inhibitors (PPIs), which are cheap and widely used. The emerging PCAB class is the direct competitive set, with drugs like Takeda's vonoprazan (approved in multiple markets) being the most advanced. Cinclus must demonstrate clear advantages in efficacy, safety, or convenience to differentiate linaprazan glurate in this crowded and cost-sensitive market.

More companies in Sweden →